Randomized controlled trials with time-to-event outcomes:: How much does prespecified covariate adjustment increase power?

被引:47
|
作者
Hernández, AV [1 ]
Eijkemans, MJC [1 ]
Steyerberg, EW [1 ]
机构
[1] Erasmus MC, Dept Publ Hlth, Ctr Clin Decis Sci, NL-3000 DR Rotterdam, Netherlands
关键词
statistical data interpretation; computer simulation; covariate; power; proportional hazards models; randomized controlled trials; sample size;
D O I
10.1016/j.annepidem.2005.09.007
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PURPOSE: We evaluated the effects of various strategies of covariate adjustment on type I error, power, and potential reduction in sample size in randomized controlled trials (RCTs) with time-to-event outcomes. METHODS: We used Cox models in simulated data sets with different treatment effects (hazard ratios [HRs] = 1, 1.4, and 1.7), covariate effects (HRs = 1, 2, and 5), covariate prevalences (10% and 50%), and censoring levels (no, low, and high). Treatment and a single covariate were dichotomous. We examined the sample size that gives the same power as an unadjusted analysis for three strategies: prespecified, significant predictive, and significant imbalance. RESULTS: Type I error generally was at the nominal level, The power to detect a true treatment effect was greater with adjusted than unadjusted analyses, especially with prespecified and significant-predictive strategies. Potential reductions in sample size with a covariate HR between 2 and 5 were between 15% and 44% (covariate prevalence 50%) and between 4% and 12% (covariate prevalence 10%). The significant imbalance strategy yielded small reductions. The reduction was greater with stronger covariate effects, but was independent of treatment effect, sample size, and censoring level. CONCLUSIONS: Adjustment for one predictive baseline characteristic yields greater power to detect a true treatment effect than unadjusted analysis, without inflation of type I error and with potentially moderate reductions in sample size. Analysis of RCTs with time-to-event outcomes should adjust for predictive covariates.
引用
收藏
页码:41 / 48
页数:8
相关论文
共 50 条
  • [21] A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome
    Royston, Patrick
    Parmar, Mahesh K. B.
    [J]. TRIALS, 2020, 21 (01)
  • [22] A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome
    Patrick Royston
    Mahesh K. B. Parmar
    [J]. Trials, 21
  • [23] Baseline characteristics and statistical power in randomized controlled trials: Selection, prognostic targeting, or covariate adjustment?
    Roozenbeek, Bob
    Maas, Andrew I. R.
    Lingsma, Hester F.
    Butcher, Isabella
    Lu, Juan
    Marmarou, Anthony
    McHugh, Gillian S.
    Weir, James
    Murray, Gordon D.
    Steyerberg, Ewout W.
    [J]. CRITICAL CARE MEDICINE, 2009, 37 (10) : 2683 - 2690
  • [24] Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?
    Karrison, Theodore
    Kocherginsky, Masha
    [J]. CLINICAL TRIALS, 2018, 15 (02) : 178 - 188
  • [25] Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes
    Uno, Hajime
    Horiguchi, Miki
    Hassett, Michael J.
    [J]. ONCOLOGIST, 2020, 25 (02): : 91 - 93
  • [26] Empirical comparison of four baseline covariate adjustment methods in analysis of continuous outcomes in randomized controlled trials
    Zhang, Shiyuan
    Paul, James
    Nantha-Aree, Manyat
    Buckley, Norman
    Shahzad, Uswa
    Cheng, Ji
    DeBeer, Justin
    Winemaker, Mitchell
    Wismer, David
    Punthakee, Dinshaw
    Avram, Victoria
    Thabane, Lehana
    [J]. CLINICAL EPIDEMIOLOGY, 2014, 6 : 227 - 235
  • [27] Estimation of ascertainment bias and its effect on power in clinical trials with time-to-event outcomes
    Greene, Erich J.
    Peduzzi, Peter
    Dziura, James
    Meng, Can
    Miller, Michael E.
    Travison, Thomas G.
    Esserman, Denise
    [J]. STATISTICS IN MEDICINE, 2021, 40 (05) : 1306 - 1320
  • [28] Guidelines for time-to-event endpoints' definitions in cancer randomized controlled trials (RCTs) for breast cancer - results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
    Gourgou-Bourgade, S.
    Dabakuyo-Yonli, S.
    Cameron, D.
    Cardoso, F.
    Poortmans, P.
    Asselain, B.
    Azria, D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S441 - S442
  • [29] Methodological review showed that time-to-event outcomes are often inadequately handled in cluster randomized trials
    Caille, Agnes
    Tavernier, Elsa
    Taljaard, Monica
    Desmee, Solene
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2021, 134 : 125 - 137
  • [30] Covariate Adjustment Strategy Increases Power in the Randomized Controlled Trial With Discrete-Time Survival Endpoints
    Safarkhani, Maryam
    Moerbeek, Mirjam
    [J]. JOURNAL OF EDUCATIONAL AND BEHAVIORAL STATISTICS, 2013, 38 (04) : 355 - 380